Mannheim Obesity Study (MOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00770276|
Recruitment Status : Active, not recruiting
First Posted : October 9, 2008
Last Update Posted : January 4, 2018
MOPS: Mannheim Obesity Pilot Study
Obesity is a central feature of the metabolic syndrome. With increasing prevalence of overweight and obesity, the incidence of WHO III° obesity will further augment. In this subset of obese patients, metabolic complications and cardiovascular risk are major clinical issues. Epidemiological data show that with increased BMI mortality rises (1). The SOS-Study demonstrated, for the first time, that bariatric surgery and consecutive weight reduction are associated with a decrease in cardiovascular and overall mortality. Significant mortality in this study was caused by cardiovascular events and cancer.
Metabolic Syndrome - MS - Despite varying definitions of the metabolic syndrome, obesity is one of its central features. Depending on the definition used, it can represent an obligate criterion (IDF) or a facultative parameter (WHO and ATP III). Even though not obligate, extreme obesity is a central risk factor for most other parameters of the metabolic syndrome.
Endothelial dysfunction -ED- represents the initial step of atherosclerosis (3). An appropriate measurement is the evaluation by retinal analysis. Epidemiological data demonstrate increased cardiovascular risk with retinal vessel pathology (4).
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Mannheim Obesity Pilot Study: Evaluation of Metabolic Und Cardiovascular Risk in Obesity|
|Study Start Date :||January 2005|
|Estimated Primary Completion Date :||February 2018|
|Estimated Study Completion Date :||January 2020|
diet and exercise
- Metabolic syndrome [ Time Frame: baseline, after 1 and 2 years ]
- Framingham risk score [ Time Frame: baseline, 1 and 2 years ]
- Subclinical atherosclerosis (IMT) [ Time Frame: baseline, 1 and 2 years ]
- Endothelial dysfunction [ Time Frame: baseline, 1 and 2 years ]
- Change in body weight [ Time Frame: baseline, 1 and 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00770276
|University hospital of Mannheim|
|Mannheim, BW, Germany, 68167|